Search Results - "Rafkin, Lisa"

Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes by Bingley, Polly J, Wherrett, Diane K, Shultz, Ann, Rafkin, Lisa E, Atkinson, Mark A, Greenbaum, Carla J

“…What will it take to bring disease-modifying therapy to clinical use in type 1 diabetes? Coordinated efforts of investigators involved in discovery,…”
Get full text

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials by Sosenko, Jay M, Skyler, Jay S, Herold, Kevan C, Schatz, Desmond A, Haller, Michael J, Pugliese, Alberto, Cleves, Mario, Geyer, Susan, Rafkin, Lisa E, Matheson, Della, Palmer, Jerry P

“…We assessed whether oral insulin slowed metabolic decline after 1 year of treatment in individuals at high risk for type 1 diabetes. Two oral insulin trials…”
Get full text

Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention by Sims, Emily K, Geyer, Susan, Johnson, Suzanne Bennett, Libman, Ingrid, Jacobsen, Laura M, Boulware, David, Rafkin, Lisa E, Matheson, Della, Atkinson, Mark A, Rodriguez, Henry, Spall, Maria, Elding Larsson, Helena, Wherrett, Diane K, Greenbaum, Carla J, Krischer, Jeffrey, DiMeglio, Linda A

“…To better understand potential facilitators of individual engagement in type 1 diabetes natural history and prevention studies through analysis of enrollment…”
Get full text

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history by Sosenko, Jay M, Skyler, Jay S, DiMeglio, Linda A, Beam, Craig A, Krischer, Jeffrey P, Greenbaum, Carla J, Boulware, David, Rafkin, Lisa E, Matheson, Della, Herold, Kevan C, Mahon, Jeffrey, Palmer, Jerry P

“…We assessed whether type 1 diabetes (T1D) can be diagnosed earlier using a new approach based on prediction and natural history in autoantibody-positive…”
Get full text

Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial―Type 1 Participants by SOSENKO, Jay M, SKYLER, Jay S, BEAM, Craig A, KRISCHER, Jeffrey P, GREENBAUM, Carla J, MAHON, Jeffrey, RAFKIN, Lisa E, MATHESON, Della, HEROLD, Kevan C, PALMER, Jerry P

“…We studied the change in the first-phase insulin response (FPIR) during the progression to type 1 diabetes (T1D). Seventy-four oral insulin trial progressors…”
Get full text

Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care 2019;42:2228-2236 by Sims, Emily K, Geyer, Susan, Johnson, Suzanne Bennett, Libman, Ingrid, Jacobsen, Laura M, Boulware, David, Rafkin, Lisa E, Matheson, Della, Atkinson, Mark A, Rodriguez, Henry, Spall, Maria, Larsson, Helena Elding, Wherrett, Diane K, Greenbaum, Carla J, Krischer, Jeffrey, DiMeglio, Linda A

Get full text

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes by SOSENKO, Jay M, SKYLER, Jay S, HEROLD, Kevan C, EISENBARTH, George, PALMER, Jerry P, MAHON, Jeffrey, KRISCHER, Jeffrey P, GREENBAUM, Carla J, RAFKIN, Lisa E, BEAM, Craig A, BOULWARE, David C, MATHESON, Della, CUTHBERTSON, David

“…OBJECTIVE We studied the utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of type 1 diabetes (T1D) risk…”
Get full text

The influence of body mass index and age on C‐peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial‐type 1 by Sosenko, Jay M, Geyer, Susan, Skyler, Jay S, Rafkin, Lisa E, Ismail, Heba M, Libman, Ingrid M, Liu, Yuk‐Fun, DiMeglio, Linda A, Evans‐Molina, Carmella, Palmer, Jerry P

“…Background/Objective The extent of influence of BMI and age on C‐peptide at the diagnosis of type 1 diabetes (T1D) is unknown. We thus studied the impact of…”
Get full text

The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results by Mahon, Jeffrey L, Sosenko, Jay M, Rafkin-Mervis, Lisa, Krause-Steinrauf, Heidi, Lachin, John M, Thompson, Clinton, Bingley, Polly J, Bonifacio, Ezio, Palmer, Jerry P, Eisenbarth, George S, Wolfsdorf, Joseph, Skyler, Jay S

“…Objectives:  TrialNet’s goal to test preventions for type 1 diabetes has created an opportunity to gain new insights into the natural history of pre‐type 1…”
Get full text

Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants by Sosenko, Jay M, Palmer, Jerry P, Rafkin, Lisa E, Krischer, Jeffrey P, Cuthbertson, David, Greenbaum, Carla J, Eisenbarth, George, Skyler, Jay S

“…OBJECTIVE: We studied the C-peptide response to oral glucose with progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants…”
Get full text

Erratum. Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787 by Sosenko, Jay M, Skyler, Jay S, Mahon, Jeffrey, Krischer, Jeffrey P, Beam, Craig A, Boulware, David C, Greenbaum, Carla J, Rafkin, Lisa E, Cowie, Catherine, Cuthbertson, David, Palmer, Jerry P

Get full text

Use of Dried Capillary Blood Sampling for Islet Autoantibody Screening in Relatives: A Feasibility Study by Bingley, Polly J, Rafkin, Lisa E, Matheson, Della, Steck, Andrea K, Yu, Liping, Henderson, Courtney, Beam, Craig A, Boulware, David C

“…Islet autoantibody testing provides the basis for assessment of risk of progression to type 1 diabetes. We set out to determine the feasibility and…”
Get more information

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months by Sosenko, Jay M, Skyler, Jay S, Beam, Craig A, Boulware, David, Mahon, Jeffrey L, Krischer, Jeffrey P, Greenbaum, Carla J, Rafkin, Lisa E, Matheson, Della, Herold, Kevan C, Palmer, Jerry P

“…We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives…”
Get full text

The Application of the Diabetes Prevention Trial-Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes by SOSENKO, Jay M, SKYLER, Jay S, PALMER, Jerry P, MAHON, Jeffrey, KRISCHER, Jeffrey P, BEAM, Craig A, BOULWARE, David C, GREENBAUM, Carla J, RAFKIN, Lisa E, COWIE, Catherine, CUTHBERTSON, David

“…We assessed the utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for identifying individuals who are highly likely to progress to type 1…”
Get full text

Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study by SOSENKO, Jay M, SKYLER, Jay S, PALMER, Jerry P, MAHON, Jeffrey, KRISCHER, Jeffrey P, BEAM, Craig A, BOULWARE, David C, GREENBAUM, Carla J, RAFKIN, Lisa E, COWIE, Catherine, CUTHBERTSON, David

“…We assessed the accuracy of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS), developed from the Diabetes Prevention Trial-Type 1 (DPT-1), in the…”
Get full text

Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) by SOSENKO, Jay M, SKYLER, Jay S, PALMER, Jerry P, KRISCHER, Jeffrey P, GREENBAUM, Carla J, MAHON, Jeffrey, RAFKIN, Lisa E, CUTHBERTSON, David, COWIE, Catherine, HEROLD, Kevan, EISENBARTH, George

“…We characterized fluctuations between states of glycemia in progressors to type 1 diabetes and studied whether those fluctuations are related to the early…”
Get full text

Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 by Sosenko, Jay M, Palmer, Jerry P, Rafkin-Mervis, Lisa, Krischer, Jeffrey P, Cuthbertson, David, Matheson, Della, Skyler, Jay S

“…OBJECTIVE:--We examined metabolic changes in the period immediately after the diagnosis of type 1 diabetes and in the period leading up to its diagnosis in…”
Get full text

Participant and Parent Experiences in the Parenteral Insulin Arm of the Diabetes Prevention Trial for Type 1 Diabetes by Johnson, Suzanne Bennett, Baughcum, Amy E, Hood, Korey, Rafkin-Mervis, Lisa E, Schatz, Desmond A

“…OBJECTIVE:--To assess participant and parent experiences in the parenteral insulin arm of the Diabetes Prevention Trial for Type 1 Diabetes (DPT-1). RESEARCH…”
Get full text

Participant and parent experiences in the oral insulin study of the Diabetes Prevention Trial for Type 1 Diabetes by Johnson, Suzanne Bennett, Baughcum, Amy E, Rafkin-Mervis, Lisa E, Schatz, Desmond A

“…Objective:  To assess the experiences of participants and parents of children in the oral insulin study of the Diabetes Prevention Trial – Type 1. Method: …”
Get full text

Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial-Type 1 by Sosenko, Jay M, Palmer, Jerry P, Rafkin-Mervis, Lisa, Krischer, Jeffrey P, Cuthbertson, David, Mahon, Jeffery, Greenbaum, Carla J, Cowie, Catherine C, Skyler, Jay S

“…OBJECTIVE: We studied the incidence of dysglycemia and its prediction of the development of type 1 diabetes in islet cell autoantibody (ICA)-positive…”
Get full text